Iterum Therapeutics (ITRM) Receives New Coverage from Analysts at Needham & Company LLC

Analysts at Needham & Company LLC began coverage on shares of Iterum Therapeutics (NASDAQ:ITRM) in a report issued on Tuesday. The firm set a “buy” rating and a $20.00 price target on the stock. Needham & Company LLC’s price target points to a potential upside of 62.60% from the stock’s current price.

Several other analysts have also commented on the stock. Leerink Swann began coverage on shares of Iterum Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $18.00 price objective on the stock. Guggenheim began coverage on shares of Iterum Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $21.00 price objective on the stock.

Shares of ITRM stock opened at $12.30 on Tuesday. Iterum Therapeutics has a 52 week low of $11.23 and a 52 week high of $13.00.

In related news, Director Patrick J. Heron acquired 456,099 shares of the stock in a transaction on Wednesday, May 30th. The shares were acquired at an average price of $13.00 per share, with a total value of $5,929,287.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Michael W. Dunne acquired 2,000 shares of the stock in a transaction on Wednesday, May 30th. The stock was bought at an average cost of $13.00 per share, for a total transaction of $26,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 965,099 shares of company stock worth $12,546,287.

Iterum Therapeutics Company Profile

There is no company description available for Iterum Therapeutics PLC.

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply